Axa
BOLD

Axa’s Audentes Therapeutics, Inc BOLD Stock Holding History

Axa’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-99,912
Closed -$2.81M – 1370
2019
Q3 		$2.81M Sell
99,912
-147
-0.1% -$5.02K 0.01% 796
2019
Q2 		$3.79M Buy
100,059
+1,820
+2% +$69.9K 0.01% 725
2019
Q1 		$3.83M Hold
98,239
– – 0.02% 712
2018
Q4 		$2.09M Buy
98,239
+20,930
+27% +$540K 0.01% 814
2018
Q3 		$3.06M Hold
77,309
– – 0.01% 797
2018
Q2 		$2.95M Buy
77,309
+984
+1% +$36.4K 0.01% 769
2018
Q1 		$2.29M Buy
+76,325
New +$2.58M 0.01% 829

Other funds holding BOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Axa's BOLD Position: Q4 2019 in Review

Axa sold out of Audentes Therapeutics, Inc (BOLD) in Q4 2019, closing a stake of 99,912 shares — an estimated $2.81M sold.

Axa first reported a position in BOLD in Q1 2018 and held it in 7 quarters. The position peaked at $3.83M in Q1 2019. 188 funds tracked by Wall St. Rank hold BOLD as of Q4 2019.

  • Axa reported no remaining Audentes Therapeutics, Inc position as of Q4 2019 after selling out during the quarter.
  • Axa sold 99,912 Audentes Therapeutics, Inc shares in Q4 2019, an estimated $2.81M.
  • Axa first reported a position in Audentes Therapeutics, Inc in Q1 2018 and held it in 7 quarters.
  • Axa's Audentes Therapeutics, Inc position peaked at $3.83M in Q1 2019.
  • 188 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q4 2019.

Based on Axa's 13F filing for Q4 2019, filed 18 Feb 2020.